Hyperphosphatemia
Conditions
Keywords
microbiome
Brief summary
This pilot study will be carried out to determine if the regular intake of iron-based Velphoro® by hyperphosphatemia patients influences the microbiome in the oral cavity and/or the gut.
Detailed description
The aim of this study is to investigate potential changes in the microbiome of the oral cavity and/or gut in patients with hyperphosphatemia following Velphoro® intake for one month. The principal intention of this study is to assess consequences of Velphoro® medication beyond phosphate control. Adherence to the drug might be compromised by e.g. staining of teeth and biofilm after chewing the product more than recommended. Most likely this is a cosmetic problem only and easy to solve by optimizing oral hygiene. The increased level of iron may have an effect on the gut microbiome which could lead to mild diarrhoea. However, the present study will assess, whether the microbiome both oral and gut changes significantly due to some iron bio-availability, although this is expected to be low with sucroferric oxyhydroxide. The ultimate goal is to improve patient adherence to the drug and to resolve potential safety concerns.
Interventions
DRUGVelphoro
4 weeks
OTHERsaliva collection
2 samples
OTHERSupragingival biofilm collection
2 samples
OTHERstool collection
2 samples
OTHERblood collection
2 samples
Sponsors
RWTH Aachen University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Suffering from hyperphosphatemia * Current treatment with a stable dose of a non-iron containing phosphate binder, * No or only parenteral iron application * Age of ≥ 18 years * Written informed consent prior to study participation * The subject is willing and able to follow the procedures outlined in the protocol Control group: * Normal renal function * No hyperphosphatemia * Age- and sex-matched and oral disease status-matched (dental caries and periodontal disease) in comparison to the hyperphosphatemia group * Written informed consent prior to study participation * The subject is willing and able to follow the procedures outlined in the protocol
Exclusion criteria
* Age less than 18 years * Currently on oral iron application * Antibiotic treatment within the last two months * Severe medical events within the last three months * Planned surgery for the duration of the sampling * Acute/chronic gastrointestinal infections * Smokers * Oral candidiasis * Oral cancer * Pregnant and lactating females * Haemochromatosis history * Committed to an institution by legal or regulatory order * Participation in a parallel interventional clinical trial * Receipt of an investigational drug within 30 days prior to inclusion into this study * The subject is mentally or legally incapacitated Only for the patient group: * Never got any phosphate binder * Allergy to Velphoro® * Celiac disease or any other chronic inflammatory bowel disease * Previous major surgery in the gastrointestinal tract
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in relative abundances of iron depending bacterial species within the microbiome from before Velphoro medication to afterwards | 4 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of distribution of bacterial species within the microbiome from baseline to after Velphoro medication | 4 weeks | via diversity measure |
Countries
Germany
Outcome results
None listed